Google’s parent company funds start-up to 'edit genes to protect against heart disease'
Alphabet is funneling funds to Verve Therapeutics, a start-up that is trying to develop a single injection containing CRISPR to gene-edit protective DNA into people at risk for heart disease.
Publication date: Available online 24 May 2019Source: American Journal of Preventive MedicineAuthor(s): Sonal J. Patil, Melissa Lewis, Erin M. Tallon, Nuha K. Wareg, Katie S. Murray, Susan G. Elliott, James J. Stevermer, Robin L. Kruse, David R. MehrContextAge-adjusted death rates for heart disease are higher in rural areas than in urban areas. Lay advisors could potentially facilitate improvement in cardiovascular health outcomes. The aim of this systematic review and meta-analysis is to estimate lay advisor intervention effects on cardiovascular health metrics in rural populations.Evidence acquisitionSearches of database...
Publication date: 25–31 May 2019Source: The Lancet, Volume 393, Issue 10186Author(s): The Lancet
Background: Kawasaki disease (KD) is one of the leading causes of acquired heart disease in children in developed nations. Epidemiologic evidence suggests that KD is related to an infectious agent; however, the cause remains unknown. Yearly incidence in Japan has been steadily increasing, but few long-term databases of KD cases from North America have been reviewed. Methods: We reviewed the epidemiology of local cases over a 16-year period to study incidence with time and temporal and geographic clustering of cases in a representative cohort in North America. Results: The yearly incidence in cases per population
Background: For pregnant women with rheumatic heart disease (RHD), the increased risk of adverse health outcomes for themselves and their babies demands a collaborative approach that addresses cultural needs. A high burden of this preventable disease persists among Aboriginal and Torres Strait Islander, M āori and Pacifica women and other vulnerable populations. Research and advocacy initiatives increasingly call for culturally-appropriate models to achieve early assessment and holistic care. The 3rd edition of the Australian RHD Guidelines address these.
Background: A study of Aboriginal women's journeys with Rheumatic Heart Disease (RHD) in Australia found that women and their families rarely had a deep understanding of the cause or implications of their disease. Despite contact with health staff, often since childhood, participants lacked understanding of the severity of their illness and its implications for childbearing. Several information/educational initiatives were developed to improve health literacy and have informed other strategies.
This study aimed to elucidate the obstetric, neonatal and cardiovascular outcomes of pregnancies in indigenous women with RHD at Townsville Hospital, a tertiary referral central in North Queensland over a decade (2008 –2018).
Rheumatic heart disease (RHD) remains a readily preventable disease. The Nganampa Health Council (NHC), Central Adelaide Local Health Network (CALHN) and RHD Program Advisory Group (RHD) have partnered to improve compliance with guideline based management of RHD in the Anunga Pitjantjatjara Yankunytjatjara (APY) lands in the far northwest of SA. For more than five years NHC has invested in a chronic disease management nurse to oversee management of complex patients, including those with RHD, establishing care plans and monitoring compliance with antibiotic prophylaxis (BLA) and echocardiographic follow up.
Aim: To identify the ethnicity and age of patient groups with severe Rheumatic Heart Disease (RHD) presenting to an urban public adult hospital or clinic setting in South East Queensland (MetroSouth) and whether valvular interventions (valve replacement, repair or valvotomy) have been performed.
Background: Approximately 3% of young Indigenous Australians suffer from rheumatic heart disease (RHD) and it is also common in Asian and African migrants. Though percutaneous balloon mitral valvotomy (PBMV) is widely performed procedure throughout the world, it is sparingly done in Queensland as evidenced by the Qcor data which shows the total number of PBMV's in 2017 was only six.
Benzathine penicillin G (BPG) has been used since the 1950s for secondary prevention acute rheumatic fever (ARF). It is approved for intramuscular (IM) injection and is unique; with blood levels present for up to 4 weeks. Australian and New Zealand Guidelines recommend BPG every 4 weeks for a minimum 10 years to prevent progression of rheumatic heart disease (RHD).